Literature DB >> 7979495

De novo facioscapulohumeral muscular dystrophy defined by DNA probe p13E-11 (D4F104S1).

P E Jardine1, M C Koch, P W Lunt, J Maynard, K D Bathke, P S Harper, M Upadhyaya.   

Abstract

Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant condition with variable age of onset and severity. Identification of a de novo DNA fragment by probe p13E-11 (D4F104S1) established the diagnosis of new mutation FSHD in 27 of 31 sporadic cases. The clinical data for these certain new mutation cases were as follows: 13 boys, 14 girls; mean age of onset 6.8 years; significant leg weakness in 19/27 (70%) (8/27 (30%) used wheelchairs at a mean age of 17.7 years); high tone sensorineural deafness in 10/27; visual acuity and direct ophthalmoscopy were normal. Congenital facial diplegia and sensorineural deafness in three children suggest that infantile FSHD is not a genetically separate disorder from FSHD. Ascertainment bias may explain the difference in severity between this group and typical familial cases. Molecular analysis for FSHD should be considered in children with either congenital or early onset facial weakness or diplegia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7979495      PMCID: PMC1029975          DOI: 10.1136/adc.71.3.221

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  35 in total

1.  Atypical facio-scapulo-humeral muscular dystrophy--a counselling dilemma.

Authors:  W Reardon; I K Temple; G Harwood; M Baraitser
Journal:  Clin Genet       Date:  1991-03       Impact factor: 4.438

2.  Studies in disorders of muscle. II Clinical manifestations and inheritance of facioscapulohumeral dystrophy in a large family.

Authors:  F H TYLER; F E STEPHENS
Journal:  Ann Intern Med       Date:  1950-04       Impact factor: 25.391

3.  Hearing loss in facioscapulohumeral dystrophy.

Authors:  T Voit; A Lamprecht; H G Lenard; H H Goebel
Journal:  Eur J Pediatr       Date:  1986-09       Impact factor: 3.183

4.  De novo DNA rearrangement in atypical facioscapulohumeral muscular dystrophy.

Authors:  P Jardine; M Jones; L Tyfield; M Upadhyaya; P Lunt
Journal:  Clin Genet       Date:  1993-09       Impact factor: 4.438

5.  Inflammatory facioscapulohumeral muscular dystrophy and Coats syndrome.

Authors:  J D Wulff; J T Lin; J J Kepes
Journal:  Ann Neurol       Date:  1982-10       Impact factor: 10.422

6.  Retinal telangiectasis in facioscapulohumeral muscular dystrophy with deafness.

Authors:  E B Gurwin; R B Fitzsimons; K S Sehmi; A C Bird
Journal:  Arch Ophthalmol       Date:  1985-11

7.  Facioscapulohumeral muscular dystrophy and accompanying hearing loss.

Authors:  M D Meyerson; E Lewis; K Ill
Journal:  Arch Otolaryngol       Date:  1984-04

8.  Evidence for heterogeneity in facioscapulohumeral muscular dystrophy (FSHD).

Authors:  J R Gilbert; J M Stajich; S Wall; S C Carter; H Qiu; J M Vance; C S Stewart; M C Speer; J Pufky; L H Yamaoka
Journal:  Am J Hum Genet       Date:  1993-08       Impact factor: 11.025

9.  Genetic counselling in facioscapulohumeral muscular dystrophy.

Authors:  P W Lunt; P S Harper
Journal:  J Med Genet       Date:  1991-10       Impact factor: 6.318

10.  X-linked and FSH dystrophies in one family.

Authors:  B R Lecky; J M MacKenzie; A P Read; D E Wilcox
Journal:  Neuromuscul Disord       Date:  1991       Impact factor: 4.296

View more
  5 in total

1.  [Facioscapulohumeral muscular dystrophy. Clinical picture, atypical forms, diagnostics, genetics].

Authors:  B Jordan; C Müller-Reible; S Zierz
Journal:  Nervenarzt       Date:  2011-06       Impact factor: 1.214

2.  Camptocormia phenotype of FSHD: a clinical and MRI study on six patients.

Authors:  Berit Jordan; Katharina Eger; Sabrina Koesling; Stephan Zierz
Journal:  J Neurol       Date:  2010-12-17       Impact factor: 4.849

3.  A multinational study on motor function in early-onset FSHD.

Authors:  Jean K Mah; Jia Feng; Marni B Jacobs; Tina Duong; Kate Carroll; Katy de Valle; Cara L Carty; Lauren P Morgenroth; Michela Guglieri; Monique M Ryan; Paula R Clemens; Mathula Thangarajh; Richard Webster; Edward Smith; Anne M Connolly; Craig M McDonald; Peter Karachunski; Mar Tulinius; Amy Harper; Avital Cnaan; Yi-Wen Chen
Journal:  Neurology       Date:  2018-03-14       Impact factor: 9.910

4.  Expression patterns of FSHD-causing DUX4 and myogenic transcription factors PAX3 and PAX7 are spatially distinct in differentiating human stem cell cultures.

Authors:  Premi Haynes; Kelly Kernan; Suk-Lin Zhou; Daniel G Miller
Journal:  Skelet Muscle       Date:  2017-06-21       Impact factor: 4.912

5.  Clinical expression of facioscapulohumeral muscular dystrophy in carriers of 1-3 D4Z4 reduced alleles: experience of the FSHD Italian National Registry.

Authors:  Ana Nikolic; Giulia Ricci; Francesco Sera; Elisabetta Bucci; Monica Govi; Fabiano Mele; Marta Rossi; Lucia Ruggiero; Liliana Vercelli; Sabrina Ravaglia; Giacomo Brisca; Chiara Fiorillo; Luisa Villa; Lorenzo Maggi; Michelangelo Cao; Maria Chiara D'Amico; Gabriele Siciliano; Giovanni Antonini; Lucio Santoro; Tiziana Mongini; Maurizio Moggio; Lucia Morandi; Elena Pegoraro; Corrado Angelini; Antonio Di Muzio; Carmelo Rodolico; Giuliano Tomelleri; Maria Grazia D'Angelo; Claudio Bruno; Angela Berardinelli; Rossella Tupler
Journal:  BMJ Open       Date:  2016-01-05       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.